Saturday, May 4, 2024

Now, Abbott Labs, A Second Tier Pharma... Has Spent About What Lilly Did, In Q1 2024, On Lobbyists.


In other years, I had compared Abbott to Baxter, but as Baxter retools and likely spins off or sells the Kidney Care business, it has dropped lobby spend to only about $320,000 in Q1 2024. So Lilly becomes a natural comparator to Abbott -- since Abbott spent a little more, and Lilly. . . a lot less, in Q1.

See at right, but here is what Abbott Labs lobbied about:

. . .S. 2477/H.R. 1770 Equitable Community Access to Pharmacist Services Act; S. 2922 Advancing Research for Chronic Pain Act of 2023; H.R. 2369 Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023; Proposals related to sterilization of medical devices; Proposals related to the President's Emergency Plan for AIDS Relief (PEPFAR); Proposals related to Department of Defense coverage of continuous glucose monitors; Proposals to advance policies related to effective pain management; Proposals related to future pandemic preparedness; Proposals related to the advancement, testing, and detection of Traumatic Brain Injury; Proposals related to the safe manufacturing of medical devices; Proposals related to the use of diagnostic tests in CLIA-waived settings. . . .

S. 1000/H.R. 1835 Saving Access to Laboratory Services Act; H.R.3674 Providing Relief and Stability for Medicare Patients Act of 2023; Proposals regarding PAMA regulations and changes to modernize and update the Clinical Laboratory Fee Schedule; Proposals related to Medicare coverage of continuous glucose monitors; Proposals related to outpatient coverage of cardiovascular medical devices. . . .

Proposals related to U.S. global health programs and pandemic preparedness; Proposals to advance global virus surveillance; Proposals related to preserving critical medical supply chains; Proposals regarding infant and child nutrition marketing. . . .

Proposals related to access to infant formula. . . . [This is spending related to a very old (since 1950s) legacy Abbott brand (Ross Labs). . . .]


Now you know -- And. . . . my exacta box bet is now down, at Churchill Downs -- let's see how they all break!

नमस्ते

No comments: